Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).
Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Usuki K, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Ota S, Ohtsuka E, Hanamura I, Suzuki Y, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Fukuhara S, Tsukasaki K, Nagai H.
Maruyama D, et al. Among authors: ota s.
Cancer Sci. 2022 Sep;113(9):3267-3270. doi: 10.1111/cas.15484. Epub 2022 Jul 31.
Cancer Sci. 2022.
PMID: 35909244
Free PMC article.
No abstract available.